The funding will be used to develop Raremark’s patient-engagement and data-analysis technology.
Hazy is an AI spin-out from UCL and is one of the businesses invested in by the UCL Technology Fund which is managed by Albion in collaboration with UCLB.
The judges looked for a track record of fundraising between April 2017 – April 2018 An impressive level of investment and exits achieved during the period A reputation for providing valuable strategic and commercial advice to portfolio companies A strong financial return for private investors
The company’s insulin and glucagon products, which are set to transform diabetes treatments, could have peak annual sales of between $200 million and $1 billion each.
Their mission is to connect healthcare systems around the world, making communication secure, transparent and flexible for healthcare professionals and patients.
Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies
UCLH Cancer Collaborative has today launched the first pilot project of an NHS ovarian cancer surveillance service for women who carry a faulty BRCA gene and have chosen not to have their ovaries and fallopian tubes removed.
Hazy offers a unique platform that allows businesses to share data responsibly and securely through a workflow tool, automatically anonymises and adapting to changing datasets.
